Literature DB >> 26264164

A Comprehensive Analysis of Influence ERCC Polymorphisms Confer on the Development of Brain Tumors.

Peiliang Geng1, Juanjuan Ou1, Jianjun Li1, Yunmei Liao1, Ning Wang1, Ganfeng Xie1, Rina Sa1, Chen Liu1, Lisha Xiang1, Houjie Liang2.   

Abstract

Within DNA repair genes, there lie a number of single nucleotide polymorphisms that may impair protein function and attenuate DNA repair capability, resulting in genomic instability and individual predisposition to malignancies. The purpose of this study was to assess the previously reported inconsistent association of polymorphisms in ERCC1 (rs11615, rs3212986), ERCC2 (rs13181, rs1799793, rs238406), and ERCC5 (rs17655) with the development of brain tumors. In the present work, we carried out a comprehensive meta-analysis of results from all published data (5 data sets for rs11615, 7 for rs3212986, 11 for rs13181, 5 for rs1799793, 3 for rs238406, and 4 for rs17655) to evaluate risk of brain tumors contributed by the polymorphisms being investigated. Either the analytic method described by Mantel and Haenszel or that proposed by DerSimonian and Laird was properly used to summarize the risk estimates (OR and 95% CI). Data analyses were done with Stata version 12.0. Meta-analyses were performed for all polymorphisms, and only rs3212986 in the ERCC1 gene showed a significant association with glioma incidence. In the homozygote comparison, we found 1.26-fold elevated risk of glioma in relation to presence of the AA genotype (OR = 1.26, 95% CI = 1.05-1.52, P OR = 0.013, P heterogeneity = 0.849, I(2) = 0.0%). We also noted that individuals with the rs3212986-AA as compared to those with rs3212986-CC/CA had a 28% higher risk to develop glioma (OR = 1.28, 95% CI = 1.06-1.53, P OR = 0.008, Pheterogeneity = 0.808, I(2) = 0.0%). No major effects were observed for Caucasians or Asians in subgroup analysis by ethnicity. ERCC1 rs3212986 is a common single nucleotide polymorphism and may contribute toward individual susceptibility for glioma. Further research in this filed is required to verify the association obtained based on a relatively small number.

Entities:  

Keywords:  Brain tumor; ERCC1; ERCC2; ERCC5; Glioma; Single nucleotide polymorphisms

Mesh:

Substances:

Year:  2015        PMID: 26264164     DOI: 10.1007/s12035-015-9371-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  48 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 2.  Polymorphisms in DNA repair genes and associations with cancer risk.

Authors:  Ellen L Goode; Cornelia M Ulrich; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-12       Impact factor: 4.254

Review 3.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 4.  How nucleotide excision repair protects against cancer.

Authors:  E C Friedberg
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

5.  Association of single-nucleotide polymorphisms in ERCC1 and ERCC2 with glioma risk.

Authors:  Lei Hui; Shuangzhu Yue; Guojun Gao; Haigang Chang; Xiangsheng Li
Journal:  Tumour Biol       Date:  2014-05-01

6.  Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas.

Authors:  Ping Yang; Thomas M Kollmeyer; Kristin Buckner; William Bamlet; Karla V Ballman; Robert B Jenkins
Journal:  Cancer       Date:  2005-06-01       Impact factor: 6.860

7.  Mutations in two short noncoding mononucleotide repeats in most microsatellite-unstable colorectal cancers.

Authors:  Tuija Hienonen; Heli Sammalkorpi; Susa Enholm; Pia Alhopuro; Thomas D Barber; Rainer Lehtonen; Nina N Nupponen; Heli Lehtonen; Reijo Salovaara; Jukka-Pekka Mecklin; Heikki Järvinen; Riitta Koistinen; Diego Arango; Virpi Launonen; Bert Vogelstein; Auli Karhu; Lauri A Aaltonen
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

8.  Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ERCC1, ERCC2, ERCC3, ERCC4, ERCC5 and XPA.

Authors:  Baocai Lu; Jing Li; Qingzu Gao; Wenfa Yu; Qinghui Yang; Xiaoyu Li
Journal:  Gene       Date:  2014-02-26       Impact factor: 3.688

9.  Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway.

Authors:  Kari Hemminki; Steinar Tretli; Jan Sundquist; Tom B Johannesen; Charlotta Granström
Journal:  Lancet Oncol       Date:  2009-04-06       Impact factor: 41.316

Review 10.  Nucleotide excision repair and cancer.

Authors:  Diana Leibeling; Petra Laspe; Steffen Emmert
Journal:  J Mol Histol       Date:  2006-07-20       Impact factor: 3.156

View more
  11 in total

1.  A Comprehensive Meta-analysis of Genetic Associations Between Key Polymorphic Loci in DNA Repair Genes and Glioma Risk.

Authors:  Ling Qi; Hong-Quan Yu; Yu Zhang; Li-Juan Ding; Dong-Hai Zhao; Peng Lv; Wei-Yao Wang; Ye Xu
Journal:  Mol Neurobiol       Date:  2016-02-03       Impact factor: 5.590

2.  Association Between the Asp312Asn, Lys751Gln, and Arg156Arg Polymorphisms in XPD and the Risk of Prostate Cancer.

Authors:  Weijin Fu; Feifan Xiao; Ruoheng Zhang; Jiatong Li; Dong Zhao; Xuandong Lin; Yanzhen Xu; Xiaowei Song; Zhibin Xie; Qiongxian Wen; Xiaoli Yang
Journal:  Technol Cancer Res Treat       Date:  2017-08-11

3.  XPG gene polymorphisms and cancer susceptibility: evidence from 47 studies.

Authors:  Jiawen Huang; Xiaoqi Liu; Ling-Ling Tang; Jian-Ting Long; Jinhong Zhu; Rui-Xi Hua; Jufeng Li
Journal:  Oncotarget       Date:  2017-06-06

4.  Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells.

Authors:  Huijun Zeng; Ningbo Xu; Yanting Liu; Boyang Liu; Zhao Yang; Zhao Fu; Changlin Lian; Hongbo Guo
Journal:  Int J Oncol       Date:  2017-06-07       Impact factor: 5.650

Review 5.  Association between the ERCC2 Asp312Asn polymorphism and risk of cancer.

Authors:  Feifan Xiao; Jian Pu; Qiongxian Wen; Qin Huang; Qinle Zhang; Birong Huang; Shanshan Huang; Aihua Lan; Yuening Zhang; Jiatong Li; Dong Zhao; Jing Shen; Huayu Wu; Yan He; Hongtao Li; Xiaoli Yang
Journal:  Oncotarget       Date:  2017-07-18

6.  The polymorphisms of miRNA-binding site in MLH3 and ERCC1 were linked to the risk of colorectal cancer in a case-control study.

Authors:  Qianye Zhang; Xiao Zheng; Xiaoxia Li; Deyu Sun; Ping Xue; Guopei Zhang; Mingyang Xiao; Yuan Cai; Cuihong Jin; Jinghua Yang; Shengwen Wu; Xiaobo Lu
Journal:  Cancer Med       Date:  2018-03-08       Impact factor: 4.452

7.  Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients.

Authors:  Ningrong Ye; Nian Jiang; Chengyuan Feng; Feiyifan Wang; Hanwen Zhang; Harrusin Xiao Bai; Li Yang; Yandong Su; Chunhai Huang; Siyi Wanggou; Xuejun Li
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

Review 8.  Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis.

Authors:  Xueyong Liu; Zhan Zhang; Chunbo Deng; Yihao Tian; Xun Ma
Journal:  Oncotarget       Date:  2017-07-19

9.  ERCC1 rs11615 polymorphism increases susceptibility to breast cancer: a meta-analysis of 4547 individuals.

Authors:  Bingjie Li; Xiaoqing Shi; Yingying Yuan; Mengle Peng; Huifang Jin; Dongchun Qin
Journal:  Biosci Rep       Date:  2018-06-21       Impact factor: 3.976

10.  Association of ERCC5 Genetic Polymorphisms With Cirrhosis and Liver Cancer.

Authors:  Gang Yang; Yuxia Yang; Xin Ma; Lijun Huang; Wenbin Li; Xuejuan Song; Huiqin Zhang; Wenwen Liu; Juanjuan Lu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.